Cargando…

Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study

BACKGROUND: Gemcitabine with platinum is one of the most important first-line treatments for metastatic urothelial cancer (mUC). However, continuation of platinum agents results in cumulative toxicities, such as nephrotoxicity, ototoxicity, and neurotoxicity, which lead to discontinuation of chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyunho, Lee, Seung-Hwan, Kim, Dong Hwan, Lee, Ji Youl, Hong, Sung-Hoo, Ha, U-Syn, Kim, In-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658126/ https://www.ncbi.nlm.nih.gov/pubmed/33209674 http://dx.doi.org/10.21037/tau-20-772

Ejemplares similares

Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells
por: Kim, Hyunho, et al.
Publicado: (2021)

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study
por: Lee, Yong Seong, et al.
Publicado: (2023)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
por: Lee, Jung Hyun, et al.
Publicado: (2014)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Influence of diabetes on the risk of urothelial cancer according to body mass index: a 10-year nationwide population-based observational study
por: Bae, Woong Jin, et al.
Publicado: (2018)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2019)

Erratum to: Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2020)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction
por: Choi, Jin Bong, et al.
Publicado: (2020)

Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma
por: Côté, Gabrielle, et al.
Publicado: (2023)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
por: Kim, Hyunho, et al.
Publicado: (2021)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
por: Rose, Tracy L., et al.
Publicado: (2018)

Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study
por: Tae, Jong Hyun, et al.
Publicado: (2022)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Retroperitoneal Single-Port Robot-Assisted Nephroureterectomy with Bladder Cuff Excision: Initial Experience and Description of the Technique
por: Bang, Seokhwan, et al.
Publicado: (2023)

Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients
por: Kim, Tae-Jung, et al.
Publicado: (2019)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2021)

Development of an Improved Animal Model of Overactive Bladder: Transperineal Ligation versus Transperitoneal Ligation in Male Rats
por: Kim, Woo Hyun, et al.
Publicado: (2016)

Effect of high-BDNF microenvironment stem cells therapy on neurogenic bladder model in rats
por: Tian, Wen Jie, et al.
Publicado: (2021)

Engineered Stem Cells Improve Neurogenic Bladder by Overexpressing SDF-1 in a Pelvic Nerve Injury Rat Model
por: Zhu, Guan Qun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1o7cg4msu6jk5ku7ltvqo2re9j